[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CO2022003789A2 - Composiciones inmunogénicas contra enfermedades entéricas y métodos para su preparación - Google Patents

Composiciones inmunogénicas contra enfermedades entéricas y métodos para su preparación

Info

Publication number
CO2022003789A2
CO2022003789A2 CONC2022/0003789A CO2022003789A CO2022003789A2 CO 2022003789 A2 CO2022003789 A2 CO 2022003789A2 CO 2022003789 A CO2022003789 A CO 2022003789A CO 2022003789 A2 CO2022003789 A2 CO 2022003789A2
Authority
CO
Colombia
Prior art keywords
polysaccharide
typhi
methods
subjects
present disclosure
Prior art date
Application number
CONC2022/0003789A
Other languages
English (en)
Inventor
Rajeev Mhalasakant Dhere
Sambhaji Shankar Pisal
Dattatreya Sarma Annamraju
Nikhil Dattatray Avalaskar
Yogesh Tukaram Hundekari
Anil Pirajirao Taklikar
Sunil Kumar Goel
Chandrashekhar Dwarkanath Kamat
Vishal Bharat Chavan
Original Assignee
Serum Institute Of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute Of India Pvt Ltd filed Critical Serum Institute Of India Pvt Ltd
Publication of CO2022003789A2 publication Critical patent/CO2022003789A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente divulgación se refiere a nuevas composiciones de vacunas inmunogénicas monovalentes y multivalentes conjugadas de polisacáridos con proteínas que comprenden un polisacárido seleccionado de cepas de Salmonela serotipo typhi; S. paratyphi A; S. typhimurium y S. enteritidis, así como a métodos alternativos mejorados de fermentación de polisacáridos, purificación de polisacáridos, conjugación de polisacáridos con proteínas y formulación estable. Además, la presente divulgación se refiere a métodos para inducir en sujetos una respuesta inmunitaria contra Salmonela typhi y enfermedades no relacionadas con typhi y/o para reducir o prevenir Salmonela typhi y enfermedades no relacionadas con typhi en sujetos que usen las composiciones divulgadas en el presente documento. La vacuna produce anticuerpos bactericidas y es útil para la prevención de gastroenteritis, fiebre entérica y tifoidea.
CONC2022/0003789A 2019-09-03 2022-03-29 Composiciones inmunogénicas contra enfermedades entéricas y métodos para su preparación CO2022003789A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921035435 2019-09-03
PCT/IN2020/050763 WO2021044436A2 (en) 2019-09-03 2020-09-02 Immunogenic compositions against enteric diseases and methods for its preparation thereof

Publications (1)

Publication Number Publication Date
CO2022003789A2 true CO2022003789A2 (es) 2022-04-19

Family

ID=72659843

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0003789A CO2022003789A2 (es) 2019-09-03 2022-03-29 Composiciones inmunogénicas contra enfermedades entéricas y métodos para su preparación

Country Status (20)

Country Link
US (1) US20230149524A1 (es)
EP (2) EP4249061A3 (es)
JP (1) JP2022546763A (es)
KR (2) KR20220087437A (es)
CN (1) CN114728053A (es)
AR (1) AR119884A1 (es)
AU (1) AU2020343943A1 (es)
BR (1) BR112022003892A2 (es)
CA (1) CA3149972A1 (es)
CO (1) CO2022003789A2 (es)
CR (1) CR20220132A (es)
EC (1) ECSP22031077A (es)
GB (2) GB2603362A (es)
IL (1) IL291006A (es)
JO (1) JOP20200214A1 (es)
MA (1) MA56283A1 (es)
MX (1) MX2022002693A (es)
PE (1) PE20221442A1 (es)
WO (1) WO2021044436A2 (es)
ZA (1) ZA202203368B (es)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
WO1998026799A1 (en) * 1996-12-18 1998-06-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugate vaccine for salmonella paratyphi a
AU771330B2 (en) 1998-08-19 2004-03-18 Baxter Healthcare Sa Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an N-acryloylated polysaccharide
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
KR101351870B1 (ko) 2005-06-27 2014-02-17 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
CN103397065A (zh) 2006-09-13 2013-11-20 雅培制药有限公司 细胞培养改良
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
FR2938265B1 (fr) 2008-11-12 2011-07-15 Univ Claude Bernard Lyon Procede pour le pilotage d'un traitement de depolymerisation par ultrasons d'un biopolymere hydrosoluble
JP5892944B2 (ja) * 2009-12-17 2016-03-23 フィナ バイオソリューションズ リミテッド ライアビリティ カンパニー コンジュゲートワクチンの製造における多糖の活性化のための化学試薬
US9011871B2 (en) * 2011-11-07 2015-04-21 University Of Maryland, Baltimore Broad spectrum vaccine against typhoidal and non-typhoidal Salmonella disease
US9283270B2 (en) * 2012-01-20 2016-03-15 Serum Institute Of India Ltd. Method for stabilization of biological molecules
TR201900778T4 (tr) 2012-01-30 2019-02-21 Serum Institute Of India Private Ltd İmmünojenik bileşim.
CN102935226B (zh) * 2012-11-16 2014-01-22 罗益（无锡）生物制药有限公司 伤寒甲型副伤寒结合疫苗及其制备方法
CN105744951B (zh) * 2013-08-24 2021-03-16 巴拉特生物技术国际有限公司 细菌疫苗及其制备方法
CN104383532A (zh) * 2014-12-02 2015-03-04 云南沃森生物技术股份有限公司 一种用乙肝表面抗原为载体蛋白的细菌多糖蛋白结合物疫苗及其制备方法
EA039487B1 (ru) * 2015-07-04 2022-02-01 Бхарат Байотек Интернэшнл Лимитед Комбинированные полисахаридные вакцинные композиции и способ получения бактериальных капсульных полисахаридов
WO2017187448A1 (en) * 2016-04-25 2017-11-02 National Institute Of Immunology A novel conjugate for vaccination against typhoid comprising chemical conjugate of vi polysaccharide and flagellin, a process for producing the same and a composition comprising the conjugate
CA3032901A1 (en) 2016-08-26 2018-03-01 Serum Institute Of India Private Limited Multivalent vaccine composition
GEP20227408B (en) * 2017-05-05 2022-08-25 Serum Institute Of India Pvt Ltd Method for removal of impurities from bacterial capsular polysaccharide based preparations
BR112020000999A2 (pt) 2017-07-18 2020-07-14 Serum Institute Of India Pvt Ltd. composição imunogênica tendo estabilidade aperfeiçoada, imunogenicidade melhorada e reatogenicidade reduzida e processo para a sua preparação
JOP20190242A1 (ar) 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها

Also Published As

Publication number Publication date
ECSP22031077A (es) 2022-05-31
CA3149972A1 (en) 2021-03-11
WO2021044436A2 (en) 2021-03-11
JP2022546763A (ja) 2022-11-08
WO2021044436A3 (en) 2021-05-27
CR20220132A (es) 2022-05-06
EP4025246A2 (en) 2022-07-13
CN114728053A (zh) 2022-07-08
EP4249061A3 (en) 2023-11-15
KR20240155975A (ko) 2024-10-29
GB202204276D0 (en) 2022-05-11
PE20221442A1 (es) 2022-09-21
AR119884A1 (es) 2022-01-19
BR112022003892A2 (pt) 2022-05-24
GB2629746A (en) 2024-11-06
US20230149524A1 (en) 2023-05-18
GB2603362A (en) 2022-08-03
KR20220087437A (ko) 2022-06-24
JOP20200214A1 (ar) 2021-03-03
IL291006A (en) 2022-05-01
EP4249061A2 (en) 2023-09-27
MA56283A1 (fr) 2023-01-31
MX2022002693A (es) 2022-07-12
AU2020343943A1 (en) 2022-03-24
ZA202203368B (en) 2022-05-25

Similar Documents

Publication Publication Date Title
CL2020001478A1 (es) Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y métodos de uso de estos.
CO2017011245A2 (es) Conjugados proteína-polisacárido de estreptococo grupo b, métodos para producir conjugados, composiciones inmunógenas que comprenden conjugados y sus usos
DOP2021000127A (es) Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso
ZA201901170B (en) Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
BR112012022669A2 (pt) composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina.
BR112014018815A8 (pt) Composição imunogênica compreendendo conjugado proteína-polissacarídeo x de n. meningitidis
TW200722101A (en) Novel composition
ME01000B (me) Živa vakcina avirulentne mycoplasma hyopneumoniae sa adjuvansom
BRPI0620163B8 (pt) composição imunogênica, vacina, processo para produzir a vacina, e, uso da composição imunogênica ou vacina
AR117921A1 (es) Cepa modificada de salmonella enterica typhi
CO2022003789A2 (es) Composiciones inmunogénicas contra enfermedades entéricas y métodos para su preparación
WO2010083477A3 (en) Broad spectrum vaccine against non-typhoidal salmonella
MX2023005221A (es) Composiciones inmunogenicas para uso en vacunas neumococicas.
BR112012004703A2 (pt) regime de imunização inicial de reforço heterólogo contra o vírus da língua azul.
AR127503A1 (es) Composiciones de gel inmunógenas que comprende antígeno de lawsonia intracellularis y/o antígeno de salmonella spp.
MX2015017677A (es) Vacuna multivalente que contiene porinas de s. typhi y s. typhimurium contra fiebre tifoidea, paratifoidea y salmonelosis no tifoideas.
AR104514A1 (es) Conjugados proteína-polisacárido de estreptococo grupo b, métodos para producir conjugados, composiciones inmunógenas que comprenden conjugados y sus usos
EA202191647A1 (ru) Композиции, содержащие конъюгаты полисахарида из streptococcus pneumoniae и белка, и способы их применения
AR088365A1 (es) Adjuvantes para vacunas polisacaridicas y las formulaciones resultantes
SG160386A1 (en) Novel composition